Top-Rated StocksTop-RatedNASDAQ:GMAB Genmab A/S (GMAB) Stock Price, News & Analysis $51.91 +0.34 (+0.66%) Closing price 03:59 PM EasternExtended Trading$52.08 +0.17 (+0.32%) As of 04:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Genmab A/S Stock (NASDAQ:GMAB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Genmab A/S alerts:Sign Up Key Stats Today's Range$50.86▼$52.0850-Day Range$32.23▼$57.2952-Week Range$23.62▼$59.97Volume2.92 million shsAverage Volume2.57 million shsMarket Capitalization$32.40 billionP/E Ratio44.37Dividend YieldN/APrice Target$53.50Consensus RatingBuy Company Overview Genmab A/S is a biotechnology company founded in 1999 and headquartered in Copenhagen, Denmark. It discovers and develops antibody-based medicines, with a focus on cancer and other serious diseases. The company develops treatments independently and with pharmaceutical partners. Its collaborations have resulted in medicines including daratumumab (Darzalex), developed with Johnson & Johnson, and epcoritamab (Epkinly), developed with AbbVie. Genmab also advances a pipeline of antibody-based therapies and uses proprietary technologies to design and engineer therapeutic antibodies. Genmab operates internationally, with activities across Europe, North America and Asia. Co-founder Jan van de Winkel serves as its chief executive officer.AI Generated. May Contain Errors. Read More Genmab A/S Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks44th Percentile Overall ScoreGMAB MarketRank™: 2.210442618605 of 5 starsGenmab A/S scored higher than 44% of companies evaluated by MarketBeat, and ranked 605th out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.8 / 5Analyst RatingBuy Consensus RatingGenmab A/S has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, 10 buy ratings, 1 hold rating, and no sell ratings.Upside/DownsideThe consensus price target for Genmab A/S is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageGenmab A/S has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Genmab A/S's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth24.22% Earnings GrowthEarnings for Genmab A/S are expected to grow by 24.22% in the coming year, from $1.28 to $1.59 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Genmab A/S is 44.23, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.98.Price to Earnings Ratio vs. SectorThe P/E ratio of Genmab A/S is 44.23, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.16.Price to Earnings Growth RatioGenmab A/S has a PEG Ratio of 2.08. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioGenmab A/S has a P/B Ratio of 5.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.57% of the float of Genmab A/S has been sold short.Short Interest Ratio / Days to CoverGenmab A/S has a short interest ratio ("days to cover") of 1.24, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Genmab A/S has recently increased by 46.38%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGenmab A/S does not currently pay a dividend.Dividend GrowthGenmab A/S does not have a long track record of dividend growth. News and Social Media1.8 / 5News Sentiment-0.18 News SentimentGenmab A/S has a news sentiment score of -0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Genmab A/S this week, compared to 7 articles on an average week.Search Interest18 people have searched for GMAB on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Genmab A/S to their MarketBeat watchlist in the last 30 days. This is a decrease of -86% compared to the previous 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Genmab A/S insiders have not sold or bought any company stock.Percentage Held by Insiders1.54% of the stock of Genmab A/S is held by insiders.Percentage Held by Institutions7.07% of the stock of Genmab A/S is held by institutions.Read more about Genmab A/S's insider trading history. Receive GMAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GMAB Stock News HeadlinesGenmab (CPSE:GMAB) Stock Could Be 47% Undervalued As Epcoritamab Approvals ExpandNovember 13, 2026 | finance.yahoo.comFY2026 EPS Estimates for Genmab A/S Reduced by HC WainwrightNovember 12, 2026 | americanbankingnews.comYou missed yesterday's deadline…In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.November 17 at 1:00 AM | Behind the Markets (Ad)Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated personsNovember 10, 2026 | globenewswire.comCapital Increase in Genmab as a Result of Employee Warrant ExerciseNovember 10, 2026 | globenewswire.comGenmab A/S Stock Earnings Estimates Reduced by HC WainwrightNovember 9, 2026 | americanbankingnews.comWhat Is Genmab (CPSE:GMAB) Signaling With New Cancer Trial Data?November 8, 2026 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Tenax Therapeutics (TENX) and Genmab (GMAB)November 7, 2026 | theglobeandmail.comSee More Headlines GMAB Stock Analysis - Frequently Asked Questions How have GMAB shares performed this year? Genmab A/S's stock was trading at $30.80 at the beginning of 2026. Since then, GMAB shares have increased by 68.1% and is now trading at $51.7820. How were Genmab A/S's earnings last quarter? Genmab A/S Sponsored ADR (NASDAQ:GMAB) released its quarterly earnings results on Thursday, November, 5th. The company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.36 by $0.20. The business had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.20 billion. Genmab A/S had a net margin of 16.97% and a trailing twelve-month return on equity of 13.67%. Read the conference call transcript. When did Genmab A/S IPO? Genmab A/S (GMAB) raised $503 million in an initial public offering (IPO) on Thursday, July 18th 2019. The company issued 27,800,000 shares at $18.11 per share. BofA Merrill Lynch, Morgan Stanley and Jefferies served as the underwriters for the IPO and Guggenheim Securities and RBC Capital Markets were co-managers. Who are Genmab A/S's major shareholders? Genmab A/S's top institutional investors include First Trust Advisors LP (0.52%), Marshall Wace LLP (0.20%), Pictet Asset Management Holding SA (0.18%) and Russell Investments Group Ltd. (0.14%). How do I buy shares of Genmab A/S? Shares of GMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Genmab A/S own? Based on aggregate information from My MarketBeat watchlists, some other companies that Genmab A/S investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Marvell Technology (MRVL), PayPal (PYPL), Palantir Technologies (PLTR), Salesforce (CRM) and Alibaba Group (BABA). Company Calendar Last Earnings11/05/2026Today11/17/2026Jefferies Global Healthcare Conference11/19/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 GMAB's financial health is in the Green zone, according to TradeSmith. GMAB has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:GMAB CIK1434265 Webwww.genmab.com Phone(457) 020-2728FaxN/AEmployees3,029Year Founded1999Price Target and Rating Average Price Target for Genmab A/S$53.50 High Price Target$80.00 Low Price Target$32.00 Potential Upside/Downside+3.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)$1.17 Trailing P/E Ratio44.37 Forward P/E Ratio32.65 P/E Growth2.08Net Income$963 million Net Margins16.97% Pretax Margin18.11% Return on Equity13.67% Return on Assets6.42% Debt Debt-to-Equity Ratio0.74 Current Ratio2.45 Quick Ratio2.43 Sales & Book Value Annual Sales$3.72 billion Price / Sales8.71 Cash Flow$1.62 per share Price / Cash Flow32.14 Book Value$10.15 per share Price / Book5.11Miscellaneous Outstanding Shares624,060,000Free Float614,448,000Market Cap$32.40 billion OptionableOptionable Beta0.73 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:GMAB) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genmab A/S Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Genmab A/S With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.